Background: Patients with primary progressive aphasia (PPA) usually develop significant behavioral disturbances with progression of the disease. We tested our clinical observation that development of disruptive agitation is more likely in semantic than in nonfluent PPA and examined which clinical variables could be associated with this behavior. Methods: We retrospectively analyzed neuropsychiatric scores and the need for behavioral treatments in semantic PPA (n = 41) and nonfluent PPA (n = 39) cases and compared first (1-3 years since the onset of symptoms) and last (5-13 years since the onset) evaluations. Clinical variables and laterality of temporal atrophy were associated with symptoms in semantic PPA cases. Results: The semantic PPA group developed more frequent (p = 0.03) and intense agitation (p = 0.0008) and had a greater need for antipsychotic drugs (p = 0.001) than the nonfluent PPA group. Presence of agitation was clearly associated with psychotic symptoms (delusions/hallucinations) but was not associated with gender, age at onset, duration of the disease, or laterality of temporal atrophy. In contrast, nonfluent PPA cases were more frequently depressed and treated with antidepressants (p = 0.0007). There were no differences in anxiety, irritability, apathy, perseverations, hyperorality, or abnormal motor behavior. Conclusions: Semantic PPA in advanced disease is frequently associated with agitation and psychotic symptoms with fewer mood symptoms, while nonfluent PPA maintains a high prevalence of depression. This implies different treatment and care and support needs for each group.

Keywords:
Frontotemporal lobar degeneration, Primary progressive aphasia, Semantic dementia, Behavior, Psychiatric symptoms, Neuropsychiatric Inventory
1.
Warren JD, Rhorer JD, Rossor MN: Frontotemporal dementia; clinical review. BMJ 2013;347:f4827.
2.
Riedl L, Mackenzie IR, Förstl H, Kurz A, Diehl-Schmid J: Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 2014;10:297-310.
3.
Karageorgiou E, Miller BL: Frontotemporal lobar degeneration: a clinical approach. Semin Neurol 2014;34:189-201.
4.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
5.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al: Classification of primary progressive aphasia and its variants. Neurology 2011;6:1006-1014.
6.
Lu PH, Mendez MF, Lee GJ, Leow AD, Lee HW, Shapira J, et al: Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2013;35:34-50.
7.
Rohrer JR, Warren JD: Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011;24:542-549.
8.
D'Alton S, Lewis J: Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci 2014;6:204.
9.
Kertesz A, Davidson W, Munoz DG: Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Dement Geriatr Cogn Disord 1999;10(suppl 1):46-49.
10.
Marczinski CA, Davidson W, Kertesz A: A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol 2004;17:185-190.
11.
Banks SJ, Weintraub S: Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia. J Geriatr Psychiatry Neurol 2008;21:133-141.
12.
Harris JM, Gall C, Thompson JC, Richardson AM, Neary D, du Plessis D, et al: Classification and pathology of primary progressive aphasia. Neurology 2013;81:1832-1839.
13.
Chare L, Hodges JR, Leyton CE, McGinley C, Tan RH, Kril JJ, Halliday GM: New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry 2014;85:865-870.
14.
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
15.
Hodges JR, Patterson K: Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol 2007;6:1004-1014.
16.
Grossman M: The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol 2012;11:545-555.
17.
Hodges JR, Mitchell J, Dawson K, Spillantini, MG, Xuereb JH, McMonagle P, et al: Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010;133:300-306.
18.
Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, et al: Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005;65:1817-1819.
19.
Boada M, Cejudo JC, Tàrraga L, López OL, Kaufer D: Neuropsychiatric Inventory Questionnaire (NPI-Q): Spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI) (in Spanish). Neurologia 2002;17:317-323.
20.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
21.
Reeves SJ, Clark-Papasavas C, Gould RL, Ffytche D, Howard RJ: Cognitive phenotype of psychotic symptoms in Alzheimer's disease: evidence for impaired visuoperceptual function in the misidentification subtype. Int J Geriatr Psychiatry 2015, Epub ahead of print.
22.
Bozeat S, Gregory CA, Ralph MA, Hodges JR: Which neuropsychiatric and behavioral features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000;69:178-186.
23.
Mychack P, Kramer JH, Boone KB, Miller BL: The influence of right frontotemporal dysfunction on social behavior in frontotemporal dementia. Neurology 2001;56(suppl 4):S11-S15.
24.
Thompson SA, Patterson K, Hodges JR: Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. Neurology 2003;61:1196-1203.
25.
Whitwell JL, Anderson VM, Scahill RI, Rossor MN, Fox NC: Longitudinal patterns of regional change on volumetric MRI in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2004;17:307-310.
26.
Medina J, Weintraub S: Depression in primary progressive aphasia. J Geriatr Psychiatry Neurol 2007;20:153-160.
27.
Singh TD, Duffy JR, Strand EA, Machulda MM, Whitwell JL, Josephs KA: Neuropsychiatric symptoms in primary progressive aphasia and apraxia of speech. Dement Geriatr Cogn Disord 2015;39:228-238.
28.
Snowden JS, Bathgate D, Varma A, Blackshaw A, Gibbons ZC, Neary D: Distinct behavioral profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 2001;70:323-332.
29.
Snowden JS, Neary D, Mann DM, Goulding PJ, Testa HJ: Progressive language disorder due to lobar atrophy. Ann Neurol 1992;31:174-183.
30.
Riedijk SR, De Vugt ME, Duivenvoorden HJ, Niermeijer MF, Van Swieten JC, Verhey FR, Tibben A: Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord 2006;22:405-412.
31.
de Vugt ME, Riedijk SR, Aalten P, Tibben A, van Swieten JC, Verhey FR: Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 2006;22:35-41.
32.
Passant U, Elfgren C, Englund E, Gustafson L: Psychiatric symptoms and their psychosocial consequences in frontotemporal dementia. Alzheimer Dis Assoc Disord 2005;19(suppl 1):15S-18S.
33.
Weintraub S, Morhardt D: Treatment, education, and resources for non-Alzheimer's dementia: one size does not fit all. Alzheimers Care Q 2005:6201-6214.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.